Ngenebio
NGeneBio Co., Ltd. was founded in October 2015, develops next generation sequencing (NGS)-based in vitro diagnostics (IVD)/companion diagnostics (CDx) products and clinical bioinformatics software (SW).
The company launched NGS-based hereditary breast/ovarian cancer panel (BRCAaccuTest) with clinical analysis SW (NGeneAnalySys) and received CE-IVD mark in Jun/2017, followed by KFDA approval in Dec/2017 based on clinical trial with over 200 BRCA clinical samples.
NGS panels for solid tumor (SOLIDaccuTest)/hematologic malignancies (HEMEaccuTest) have been launched, inclusive of clinical data analysis and report generation SW platform. In support of oncology clinical lab community, our mission is to provide clinically validated NGS-IVD/CDx products/services with the convergence of innovative biotechnology and bioinformatics.
The company launched short tandem repeat (STR) kit for genetic profiling (forensic & paternity test), IDaccuTest, compatible with Sanger sequencers.
